Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06841185 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

Name: A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma — clinical trial record (NCT06841185)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorShanghai Henlius Biotech

Started2025-04-30

View on ClinicalTrials.gov ↗

Shanghai Henlius Biotech

56 trials monitored

See all monitored trials

Liver Cancer

1,505 trials monitored

See 60 trials at risk

This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Trial Details

NCT Number	NCT06841185
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	656 participants
Start Date	2025-04-30
Primary Completion	2027-06-06 (estimated)
Study Completion	2028-05-05 (estimated)
Updated on ClinicalTrials.gov	2025-02-24